- Home
- REGN vs EPD Comparison
REGN vs EPD Comparison
Compare REGN & EPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- EPD
- Stock Information
- Founded
- REGN 1988
- EPD 1968
- Country
- REGN United States
- EPD United States
- Employees
- REGN N/A
- EPD N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- EPD Natural Gas Distribution
- Sector
- REGN Health Care
- EPD Utilities
- Exchange
- REGN Nasdaq
- EPD Nasdaq
- Market Cap
- REGN 59.5B
- EPD 68.2B
- IPO Year
- REGN 1991
- EPD 1998
- Fundamental
- Price
- REGN $560.00
- EPD $31.78
- Analyst Decision
- REGN Buy
- EPD Buy
- Analyst Count
- REGN 23
- EPD 13
- Target Price
- REGN $794.83
- EPD $36.00
- AVG Volume (30 Days)
- REGN 972.9K
- EPD 3.3M
- Earning Date
- REGN 10-30-2025
- EPD 10-28-2025
- Dividend Yield
- REGN 0.63%
- EPD 6.86%
- EPS Growth
- REGN 5.03
- EPD 2.20
- EPS
- REGN 39.67
- EPD 2.68
- Revenue
- REGN $14,214,200,000.00
- EPD $54,756,000,000.00
- Revenue This Year
- REGN N/A
- EPD N/A
- Revenue Next Year
- REGN $4.86
- EPD $9.50
- P/E Ratio
- REGN $14.12
- EPD $11.86
- Revenue Growth
- REGN 5.38
- EPD N/A
- 52 Week Low
- REGN $476.49
- EPD $27.77
- 52 Week High
- REGN $1,170.58
- EPD $34.63
- Technical
- Relative Strength Index (RSI)
- REGN 46.27
- EPD 52.91
- Support Level
- REGN $552.98
- EPD $31.51
- Resistance Level
- REGN $570.76
- EPD $32.00
- Average True Range (ATR)
- REGN 15.16
- EPD 0.38
- MACD
- REGN -2.91
- EPD -0.01
- Stochastic Oscillator
- REGN 16.26
- EPD 46.60
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About EPD Enterprise Products Partners L.P.
Enterprise Products Partners is a master limited partnership that transports and processes natural gas, natural gas liquids, crude oil, refined products, and petrochemicals. It is one of the largest midstream companies, with operations servicing most producing regions in the continental US. Enterprise is particularly dominant in the NGL market and is one of the few MLPs that provide midstream services across the full hydrocarbon value chain.